Naoto T Ueno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2474462/publications.pdf

Version: 2024-02-01

341 papers	17,936 citations	17405 63 h-index	18606 119 g-index
355 all docs	355 docs citations	355 times ranked	27293 citing authors

#	Article	IF	Citations
1	Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment. Journal of the National Cancer Institute, 2022, 114, 97-108.	3.0	15
2	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. Npj Breast Cancer, 2022, 8, 12.	2.3	6
3	A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. Scientific Reports, 2022, 12, 2478.	1.6	2
4	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022, 6, e2000368.	1.5	9
5	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers, 2022, 14, 1323.	1.7	4
6	Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. Nature Communications, 2022, 13, 1791.	5.8	8
7	NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. Journal of the National Cancer Institute, 2022, 114, 579-591.	3.0	25
8	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2878-2889.	3.2	10
9	Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opinion on Therapeutic Targets, 2022, 26, 405-425.	1.5	3
10	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. Seminars in Ultrasound, CT and MRI, 2021, 42, 164-183.	0.7	0
11	Update on systemic treatment for newly diagnosed inflammatory breast cancer. Journal of Advanced Research, 2021, 29, 1-12.	4.4	20
12	Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathwayâ€“Dependent Apoptosis. Molecular Cancer Therapeutics, 2021, 20, 296-306.	1.9	14
13	Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Research and Treatment, 2021, 186, 273-283.	1.1	47
14	Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Communications Biology, 2021, 4, 72.	2.0	29
15	Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase. JCO Oncology Practice, 2021, 17, 177-183.	1.4	10
16	The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 4265-4274.	0.7	11
17	The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy. Cancers, 2021, 13, 608.	1.7	4
18	Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorganic and Medicinal Chemistry, 2021, 32, 116013.	1.4	7

#	Article	IF	Citations
19	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS ONE, 2021, 16, e0250057.	1.1	3
20	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Medicine, 2021, 13, 70.	3.6	8
21	Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer. Cancers, 2021, 13, 2650.	1.7	11
22	PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines, 2021, 9, 740.	1.4	10
23	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Research and Treatment, 2021, 189, 455-461.	1.1	6
24	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nature Communications, 2021, 12, 3528.	5.8	108
25	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 8610-8621.	0.7	7
26	Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Research and Treatment, 2021, 189, 333-345.	1.1	1
27	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5365-5375.	3.2	29
28	Inflammatory Breast Cancer at the Extremes of Age. Annals of Surgical Oncology, 2021, 28, 5626-5634.	0.7	5
29	Inflammatory breast cancer appearance at presentation is associated with overall survival. Cancer Medicine, 2021, 10, 6261-6272.	1.3	10
30	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Molecular Oncology, 2021, 15, 2752-2765.	2.1	19
31	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers, 2021, 13, 4839.	1.7	18
32	Estrogen Receptor Î²-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. Cancer Research, 2021, 81, 2399-2414.	0.4	7
33	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1929724.	2.1	22
34	ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells. Biomedicines, 2021, 9, 1410.	1.4	6
35	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Scientific Reports, 2021, 11, 22242.	1.6	11
36	Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. World Journal of Oncology, 2021, 12, 183-194.	0.6	2

#	Article	IF	Citations
37	â€œWhy and Whatâ€•for the optimal management of inflammatory breast cancer. Chinese Clinical Oncology, 2021, 10, 54-54.	0.4	0
38	Phase II study of Radiumâ€223 dichloride combined with hormonal therapy for hormone receptorâ€positive, boneâ€dominant metastatic breast cancer. Cancer Medicine, 2020, 9, 1025-1032.	1.3	19
39	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in nonâ€inflammatory breast cancers. Molecular Oncology, 2020, 14, 504-519.	2.1	23
40	Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Molecular Therapy - Oncolytics, 2020, 18, 579-586.	2.0	13
41	The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â^') metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 729-739.	1.1	2
42	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology, 2020, 27, 4603-4612.	0.7	12
43	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers, 2020, 12, 3105.	1.7	1
44	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. JCO Clinical Cancer Informatics, 2020, 4, 839-853.	1.0	11
45	Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers, 2020, 12, 2479.	1.7	25
46	NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers, 2020, 12, 3711.	1.7	20
47	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. JCO Clinical Cancer Informatics, 2020, 4, 583-601.	1.0	4
48	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer, 2020, 20, 430.	1.1	4
49	The CD151â€midkine pathway regulates the immune microenvironment in inflammatory breast cancer. Journal of Pathology, 2020, 251, 63-73.	2.1	14
50	Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells, 2020, 9, 515.	1.8	5
51	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist, 2020, 25, e909-e919.	1.9	2
52	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Research, 2020, 80, 1304-1315.	0.4	37
53	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS ONE, 2020, 15, e0231953.	1.1	18
54	JNK Signaling in Stem Cell Self-Renewal and Differentiation. International Journal of Molecular Sciences, 2020, 21, 2613.	1.8	50

#	Article	IF	Citations
55	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStreamÂ® in patients with breast cancer treated with primary systemic therapy. PLoS ONE, 2020, 15, e0229903.	1.1	23
56	Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. European Journal of Surgical Oncology, 2020, 46, 1588-1595.	0.5	15
57	Inflammatory breast cancer cells are characterized by abrogated TGFÎ²1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment, 2020, 180, 385-395.	1.1	18
58	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Scientific Reports, 2020, 10, 8537.	1.6	28
59	Abstract P3-01-10: Ndrg1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis. , 2020, , .		4
60	Title is missing!. , 2020, 15, e0231953.		0
61	Title is missing!. , 2020, 15, e0231953.		0
62	Title is missing!. , 2020, 15, e0231953.		0
63	Title is missing!. , 2020, 15, e0231953.		0
64	Title is missing!. , 2020, 15, e0231953.		0
65	Title is missing!. , 2020, 15, e0231953.		0
66	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986606.	1.4	35
67	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer, 2019, 10, 3344-3351.	1.2	19
68	Patient reported outcomes can improve performance status assessment: a pilot study. Journal of Patient-Reported Outcomes, 2019, 3, 41.	0.9	22
69	Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS ONE, 2019, 14, e0222336.	1.1	17
70	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Practical Radiation Oncology, 2019, 9, 402-409.	1.1	8
71	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. Journal of Cancer, 2019, 10, 2635-2642.	1.2	3
72	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. British Journal of Cancer, 2019, 120, 1105-1112.	2.9	22

#	Article	IF	Citations
73	Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Research and Treatment, 2019, 176, 545-556.	1.1	16
74	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	1.6	70
75	Imaging features of triple-negative breast cancers according to androgen receptor status. European Journal of Radiology, 2019, 114, 167-174.	1.2	14
76	Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Research and Treatment, 2019, 175, 339-351.	1.1	17
77	Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 399-412.	1.9	9
78	Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. Oncologist, 2019, 24, 1322-1330.	1.9	6
79	Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene, 2019, 38, 2135-2150.	2.6	26
80	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Investigational New Drugs, 2019, 37, 345-351.	1.2	28
81	Bone Metastasis of Breast Cancer. Advances in Experimental Medicine and Biology, 2019, 1152, 105-129.	0.8	90
82	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Research and Treatment, 2018, 169, 615-623.	1.1	12
83	Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer, 2018, 124, 2299-2305.	2.0	11
84	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. American Journal of Clinical Pathology, 2018, 149, 253-261.	0.4	22
85	Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer, 2018, 124, 866-866.	2.0	0
86	Inflammatory breast cancer biology: the tumour microenvironment is key. Nature Reviews Cancer, 2018, 18, 485-499.	12.8	235
87	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Human Pathology, 2018, 77, 121-129.	1.1	20
88	The Emerging Impact of Social Media on Cancer Patient Education in Japan. Oncologist, 2018, 23, e105-e106.	1.9	1
89	Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory BreastÂCancer. Clinical Breast Cancer, 2018, 18, e73-e77.	1.1	28
90	BRCA mutations in women with inflammatory breast cancer. Cancer, 2018, 124, 466-474.	2.0	14

#	Article	IF	Citations
91	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. European Journal of Cancer, 2018, 89, 64-71.	1.3	3
92	Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	43
93	ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAKâ€“AKTâ€“mTOR Signaling Pathway. Molecular Cancer Therapeutics, 2018, 17, 2689-2701.	1.9	57
94	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE, 2018, 13, e0204372.	1.1	16
95	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE, 2018, 13, e0204513.	1.1	34
96	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. Journal of Cancer, 2018, 9, 3640-3646.	1.2	19
97	Inflammatory Breast Cancer. Surgical Clinics of North America, 2018, 98, 787-800.	0.5	63
98	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clinical Biomechanics, 2018, 56, 61-69.	0.5	5
99	CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. Scientific Reports, 2018, 8, 9427.	1.6	30
100	Survivorship and Advocacy in Inflammatory Breast Cancer. Journal of Cancer, 2018, 9, 1430-1436.	1.2	5
101	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer, 2018, 9, 1437-1447.	1.2	84
102	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clinical Breast Cancer, 2018, 18, e1283-e1288.	1.1	10
103	Reply to â€˜A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18â€™. Breast, 2018, 39, 148-149.	0.9	2
104	Clinically relevant inflammatory breast cancer patient-derived xenograftâ€“derived ex vivo model for evaluation of tumor-specific therapies. PLoS ONE, 2018, 13, e0195932.	1.1	13
105	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878685.	1.4	5
106	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology, 2018, 4, 1207.	3.4	56
107	Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Research and Treatment, 2018, 171, 501-511.	1.1	10
108	Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget, 2018, 9, 6872-6882.	0.8	7

#	Article	IF	Citations
109	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer, 2017, 116, 509-514.	2.9	18
110	Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 463-479.	1.9	44
111	Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272.	1.1	27
112	Outcomes in patients with earlyâ€stage breast cancer who underwent a 21â€gene expression assay. Cancer, 2017, 123, 2422-2431.	2.0	19
113	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Research and Treatment, 2017, 164, 57-67.	1.1	31
114	Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clinical Cancer Research, 2017, 23, 4780-4792.	3.2	35
115	Novel therapeutic strategies in the treatment of triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 493-511.	1.4	58
116	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). Neoplasia, 2017, 19, 564-573.	2.3	25
117	Inflammatory breast cancer: a proposed conceptual shift in the UICCâ€“AJCC TNM staging system. Lancet Oncology, The, 2017, 18, e228-e232.	5.1	74
118	Androgen Receptor Function and Androgen Receptorâ€“Targeted Therapies in Breast Cancer. JAMA Oncology, 2017, 3, 1266.	3.4	166
119	Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer, 2017, 123, 2618-2625.	2.0	11
120	Reply to â€˜Comment on â€˜Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapyâ€™â€™. British Journal of Cancer, 2017, 116, e11-e11.	2.9	0
121	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature, 2017, 543, 714-718.	13.7	229
122	Association between weight gain during adjuvant chemotherapy for earlyâ€stage breast cancer and survival outcomes. Cancer Medicine, 2017, 6, 2515-2522.	1.3	28
123	Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 166, 819-832.	1.1	16
124	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Annals of Surgical Oncology, 2017, 24, 2981-2988.	0.7	30
125	Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology, 2017, 28, 2420-2428.	0.6	114
126	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Research, 2017, 19, 93.	2.2	45

#	Article	IF	Citations
127	In response to â€œoutcomes of patients with inflammatory breast cancer treated by breast conserving surgeryâ€• the argument against breast conservation and sentinel lymph node biopsy in IBC. Breast Cancer Research and Treatment, 2017, 165, 779-781.	1.1	4
128	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. Journal of Cancer, 2017, 8, 2026-2032.	1.2	25
129	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614.	1.2	15
130	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. Journal of Cancer, 2017, 8, 2004-2009.	1.2	14
131	Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. PLoS ONE, 2017, 12, e0170081.	1.1	5
132	Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS ONE, 2017, 12, e0185231.	1.1	20
133	Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. Journal of Cancer, 2017, 8, 1726-1732.	1.2	5
134	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer, 2017, 8, 1045-1052.	1.2	9
135	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. Journal of Cancer, 2017, 8, 1009-1017.	1.2	5
136	MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochemical and Biophysical Research Communications, 2017, 489, 484-489.	1.0	9
137	Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. Molecular Therapy - Oncolytics, 2017, 6, 1-9.	2.0	24
138	Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer.. Journal of Clinical Oncology, 2017, 35, 11501-11501.	0.8	2
139	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget, 2017, 8, 35656-35668.	0.8	44
140	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 2017, 8, 14897-14911.	0.8	35
141	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget, 2017, 8, 67904-67917.	0.8	40
142	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. Oncotarget, 2017, 8, 70481-70495.	0.8	14
143	A target of potential RELAvance in inflammatory breast cancer. Oncotarget, 2017, 8, 25835-25836.	0.8	0
144	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. Journal of Cancer, 2016, 7, 947-956.	1.2	9

#	Article	IF	Citations
145	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0152585.	1.1	14
146	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist, 2016, 21, 21-27.	1.9	19
147	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw026.	3.0	70
148	Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Research and Treatment, 2016, 156, 427-440.	1.1	19
149	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	13.7	1,760
150	Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Research and Treatment, 2016, 160, 101-109.	1.1	12
151	Impact of clinical trial on survival outcomes. Breast Cancer Research and Treatment, 2016, 159, 273-281.	1.1	3
152	Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis, 2016, 37, bgw097.	1.3	22
153	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12780-12785.	3.3	31
154	Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control, 2016, 27, 359-366.	0.8	38
155	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern Pathology, 2016, 29, 330-346.	2.9	33
156	MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity inÂBreast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 791-799.	0.4	21
157	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 11532-11532.	0.8	2
158	Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay.. Journal of Clinical Oncology, 2016, 34, 559-559.	0.8	1
159	Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.. Journal of Clinical Oncology, 2016, 34, 609-609.	0.8	4
160	Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget, 2016, 7, 82482-82492.	0.8	78
161	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget, 2016, 7, 76362-76373.	0.8	22
162	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7, 18531-18540.	0.8	38

#	Article	IF	Citations
163	Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget, 2016, 7, 28329-28339.	0.8	54
164	Inflammatory and Locally Advanced Breast Cancer. , 2016, , 411-435.		0
165	Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.. Journal of Clinical Oncology, 2016, 34, 1087-1087.	0.8	3
166	Prognosis for patients with metastatic breast cancer who achieve a noâ€evidenceâ€ofâ€disease status after systemic or local therapy. Cancer, 2015, 121, 4324-4332.	2.0	34
167	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 242-247.	0.6	26
168	Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. Journal of Cancer, 2015, 6, 1306-1319.	1.2	18
169	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. Journal of Cancer, 2015, 6, 310-318.	1.2	20
170	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 2015, 6, 12890-12908.	0.8	92
171	Disulfiram (DSF) acts as a copper ionophore to induce copperâ€dependent oxidative stress and mediate antiâ€tumor efficacy in inflammatory breast cancer. Molecular Oncology, 2015, 9, 1155-1168.	2.1	168
172	Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future. Women's Health, 2015, 11, 1-5.	0.7	9
173	Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research, 2015, 17, 2.	2.2	36
174	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. Clinical Breast Cancer, 2015, 15, 458-466.	1.1	10
175	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment, 2015, 152, 407-416.	1.1	68
176	High-Density and Very-Low-Density LipoproteinÂHave Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to Radiation in Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 1072-1080.	0.4	33
177	Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Research, 2015, 17, 42.	2.2	49
178	Challenging a Traditional Paradigm. Plastic and Reconstructive Surgery, 2015, 135, 262e-269e.	0.7	21
179	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer. JAMA Oncology, 2015, 1, 1311.	3.4	65
180	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv250.	3.0	25

#	Article	IF	Citations
181	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Molecular Cancer Therapeutics, 2015, 14, 2773-2781.	1.9	61
182	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 144, 713-721.	0.4	34
183	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of Clinical Oncology, 2015, 33, 2753-2762.	0.8	372
184	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Molecular Cancer Therapeutics, 2015, 14, 2687-2699.	1.9	15
185	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment, 2015, 154, 495-508.	1.1	52
186	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Letters, 2015, 356, 374-381.	3.2	10
187	Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers. Clinical Breast Cancer, 2015, 15, 37-42.	1.1	6
188	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS ONE, 2015, 10, e0132710.	1.1	121
189	Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience, 2015, 2, 576-580.	0.9	42
190	Functional consequence of theMET-T1010I polymorphism in breast cancer. Oncotarget, 2015, 6, 2604-2614.	0.8	34
191	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. PLoS ONE, 2014, 9, e83113.	1.1	91
192	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Journal of Cancer, 2014, 5, 745-753.	1.2	46
193	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research, 2014, 16, 440.	2.2	94
194	Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database. Journal of Clinical Oncology, 2014, 32, 2018-2024.	0.8	113
195	Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer, 2014, 120, 1319-1328.	2.0	57
196	Gene Signatureâ€“Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research, 2014, 20, 5265-5271.	3.2	28
197	Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. Oncologist, 2014, 19, 909-914.	1.9	15
198	Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining. Clinical Breast Cancer, 2014, 14, e81-e88.	1.1	17

#	Article	IF	Citations
199	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Translational Medicine, 2014, 3, 849-856.	1.6	69
200	The Role of Inflammation in Inflammatory Breast Cancer. Advances in Experimental Medicine and Biology, 2014, 816, 53-73.	0.8	53
201	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 58.	3.5	23
202	A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Research and Treatment, 2014, 146, 259-272.	1.1	38
203	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus, 2014, 3, 166.	1.2	20
204	Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer, 2014, 120, 1775-1779.	2.0	8
205	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	2.9	43
206	18F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1809-1816.	3.3	18
207	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research, 2013, 73, 6516-6525.	0.4	70
208	Latest biopsy approach for suspected metastases in patients with breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 711-719.	12.5	22
209	Breast Cancer Biomarkers: Utility in Clinical Practice. Current Breast Cancer Reports, 2013, 5, 284-292.	0.5	16
210	A Comparison of Epidemiology, Biology, and Prognosis of Inflammatory Breast Cancer in Japanese and US Populations. Clinical Breast Cancer, 2013, 13, 460-464.	1.1	11
211	A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer. Clinical Breast Cancer, 2013, 13, 24-30.	1.1	33
212	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Research, 2013, 15, R112.	2.2	46
213	Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Research and Treatment, 2013, 137, 523-531.	1.1	25
214	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	3.2	130
215	Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Research and Treatment, 2013, 138, 761-772.	1.1	56
216	Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP. Molecular Cancer Therapeutics, 2013, 12, 1099-1111.	1.9	16

#	Article	IF	Citations
217	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.	3.2	597
218	Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer, 2013, 4, 679-685.	1.2	4
219	Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient. Journal of Cancer, 2013, 4, 697-702.	1.2	5
220	The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer. PLoS ONE, 2013, 8, e71508.	1.1	46
221	A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells. Cancer Hallmarks, 2013, 1, 59-66.	0.9	19
222	Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.. Journal of Clinical Oncology, 2013, 31, 532-532.	0.8	1
223	Bone Metastasis of Breast Cancer. , 2013, , 189-209.		0
224	Signaling Pathways in Inflammatory Breast Cancer. , 2012, , 151-160.		0
225	Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Journal of Clinical Oncology, 2012, 30, 729-734.	0.8	231
226	Epithelialâ€“Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2012, 11, 2526-2534.	1.9	194
227	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leukemia and Lymphoma, 2012, 53, 1239-1241.	0.6	22
228	Metastasis in the Breast Mimicking Inflammatory Breast Cancer. Journal of Clinical Oncology, 2012, 30, e202-e206.	0.8	6
229	Phase II Study of Gonadotropinâ€Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients. Oncologist, 2012, 17, 233-238.	1.9	26
230	MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15â€“Dependent Manner in a Mouse Xenograft Model. Molecular Cancer Therapeutics, 2012, 11, 360-369.	1.9	23
231	Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. Journal of Clinical Oncology, 2012, 30, 593-599.	0.8	361
232	Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer, 2012, 3, 369-380.	1.2	65
233	Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 2012, 17, 891-899.	1.9	127
234	Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment, 2012, 136, 331-345.	1.1	529

#	Article	IF	Citations
235	Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clinical Breast Cancer, 2012, 12, 264-269.	1.1	87
236	Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients WithÂInflammatory Breast Cancer Influences RadiationÂTreatment Field Designs. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1381-1386.	0.4	42
237	Microfluidics separation reveals the stem-cellâ€“like deformability of tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18707-18712.	3.3	186
238	Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/Î²â€Catenin Signaling. Stem Cells, 2012, 30, 2366-2377.	1.4	100
239	Bone Metastases. , 2012, , 591-609.		2
240	Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with boneâ€only metastases. Cancer, 2012, 118, 2039-2047.	2.0	19
241	Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer, 2012, 19, 191-199.	1.3	60
242	Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology, 2012, 17, 96-104.	1.0	80
243	Serum HER2 levels determined by two methods in patients with metastatic breast cancer. International Journal of Clinical Oncology, 2012, 17, 55-62.	1.0	7
244	Systemic and Targeted Therapy. , 2012, , 85-99.		0
245	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study. , 2012, , 225-242.		0
246	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer. , 2012, , 127-138.		0
247	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research, 2011, 13, R67.	2.2	188
248	Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. Journal of Cancer, 2011, 2, 435-442.	1.2	22
249	Targeting EGFR in Triple Negative Breast Cancer. Journal of Cancer, 2011, 2, 324-328.	1.2	128
250	Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecologic Oncology, 2011, 122, 641-647.	0.6	19
251	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 125, 785-795.	1.1	68
252	Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology, 2011, 16, 596-600.	1.0	10

#	Article	IF	Citations
253	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. Cancer, 2011, 117, 1819-1826.	2.0	121
254	Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer, 2011, 117, 5476-5484.	2.0	61
255	Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International Journal of Cancer, 2011, 129, 417-423.	2.3	101
256	Initial Staging Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Breast Cancer. Oncologist, 2011, 16, 772-782.	1.9	16
257	Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. Oncologist, 2011, 16, 956-965.	1.9	12
258	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 305, 1873.	3.8	531
259	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. Journal of Clinical Oncology, 2011, 29, 3214-3223.	0.8	89
260	Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist, 2011, 16, 1675-1683.	1.9	86
261	High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials. Journal of Clinical Oncology, 2011, 29, 3224-3231.	0.8	66
262	Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis. Oncologist, 2011, 16, 155-164.	1.9	59
263	FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer. Oncologist, 2011, 16, 1111-1119.	1.9	73
264	Information Sharing and Case Conference Among the Multidisciplinary Team Improve Patientsâ€™ Perceptions of Care. Open Nursing Journal, 2011, 5, 79-85.	0.2	13
265	Expression of phosphoprotein enriched in astrocytes 15ÂkDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. Journal of Neuro-Oncology, 2010, 100, 449-457.	1.4	20
266	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. Ca-A Cancer Journal for Clinicians, 2010, 60, 351-375.	157.7	298
267	Targeted therapy in inflammatory breast cancer. Cancer, 2010, 116, 2758-2759.	2.0	11
268	Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions. International Journal of Radiation Oncology Biology Physics, 2010, 76, 889-895.	0.4	39
269	Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. Breast Journal, 2010, 16, 327-330.	0.4	32
270	PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase. Clinical Cancer Research, 2010, 16, 1802-1811.	3.2	38

#	Article	IF	Citations
271	¹⁸F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. Journal of Nuclear Medicine, 2010, 51, 1213-1218.	2.8	60
272	Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptorâ€“Expressing Breast Cancer. Molecular Cancer Therapeutics, 2010, 9, 3090-3099.	1.9	21
273	ABC conceptual model of effective multidisciplinary cancer care. Nature Reviews Clinical Oncology, 2010, 7, 544-547.	12.5	17
274	Is High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal?. Women's Health, 2010, 6, 481-485.	0.7	4
275	Future directions of bone-targeted therapy for metastatic breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 641-651.	12.5	97
276	Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. Journal of Cancer, 2010, 1, 80-92.	1.2	205
277	Lapatinib in the Treatment of Breast Cancer. Clinical Medicine Therapeutics, 2009, 1, CMT.S52.	0.1	0
278	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research, 2009, 15, 6639-6648.	3.2	113
279	A novel hTERT promoterâ€“driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics, 2009, 8, 2375-2382.	1.9	34
280	Interleukin-2 and granulocyteâ€“macrophageâ€“colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. International Journal of Hematology, 2009, 90, 627-634.	0.7	5
281	Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Science, 2009, 100, 2275-2282.	1.7	45
282	Circulating Tumor Cells and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3303-3311.	0.8	139
283	Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in Perceived Importance Over Time. Biology of Blood and Marrow Transplantation, 2009, 15, 1465-1474.	2.0	36
284	Pilot Study of Targeted Skeletal Radiation Therapy for Bone-Only Metastatic Breast Cancer. Clinical Breast Cancer, 2009, 9, 173-177.	1.1	9
285	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Research, 2009, 11, R12.	2.2	65
286	Molecular targets for treatment of inflammatory breast cancer. Nature Reviews Clinical Oncology, 2009, 6, 387-394.	12.5	52
287	Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncology, The, 2009, 10, 606-614.	5.1	154
288	Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncology, 2009, 5, 1585-1603.	1.1	51

#	Article	IF	Citations
289	Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. Blood, 2009, 114, 868-868.	0.6	2
290	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. Blood, 2009, 114, 3213-3213.	0.6	0
291	The Medical Treatment of Inflammatory Breast Cancer. Seminars in Oncology, 2008, 35, 64-71.	0.8	38
292	PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival. Cancer Research, 2008, 68, 9302-9310.	0.4	62
293	Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics, 2008, 7, 1846-1850.	1.9	70
294	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 2008, 93, 257-264.	1.7	141
295	Stem Cell Transplantation for Metastatic and High-Risk Nonmetastatic Breast Cancer: A Novel Treatment Approach. , 2008, , 387-410.		0
296	Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nature Clinical Practice Oncology, 2008, 5, 78-89.	4.3	29
297	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. Blood, 2008, 112, 5440-5440.	0.6	1
298	Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. Cancer Research, 2007, 67, 5779-5788.	0.4	107
299	Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Molecular Cancer Therapeutics, 2007, 6, 2168-2177.	1.9	65
300	Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Molecular Cancer Therapeutics, 2007, 6, 227-235.	1.9	23
301	Whatâ€™s Past Is Prologue: Lessons Learned and the Need for Further Development of Allogeneic Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma. Biology of Blood and Marrow Transplantation, 2007, 13, 31-33.	2.0	12
302	Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 975-985.	2.0	4
303	Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Research, 2007, 9, R41.	2.2	5
304	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. Clinical Breast Cancer, 2007, 7, 34-42.	1.1	141
305	Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer, 2007, 110, 1436-1444.	2.0	194
306	ZevalinÂ®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. Blood, 2007, 110, 620-620.	0.6	5

#	Article	IF	Citations
307	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. Blood, 2007, 110, 48-48.	0.6	0
308	Trials and Tribulations in Developing Clinical Trials of Gene Therapy. , 2007, , 387-398.		0
309	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clinical Breast Cancer, 2007, 7, 471-9.	1.1	67
310	High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplantation, 2006, 37, 929-935.	1.3	4
311	Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2910-2916.	0.8	178
312	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2006, 108, 315-315.	0.6	14
313	Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. Cancer Research, 2005, 65, 8406-8413.	0.4	27
314	Cyclin Aâ€“associated kinase activity is needed for paclitaxel sensitivity. Molecular Cancer Therapeutics, 2005, 4, 1039-1046.	1.9	20
315	Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica, 2005, 90, 1725-6.	1.7	16
316	Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint. Cancer Research, 2004, 64, 2502-2508.	0.4	248
317	Graftâ€”Versusâ€”Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier. Journal of Clinical Oncology, 2004, 22, 3846-3847.	0.8	3
318	Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, HerceptinÂ®) conjugated polyethylenimine. Journal of Controlled Release, 2004, 97, 357-369.	4.8	138
319	Bone Imaging in Metastatic Breast Cancer. Journal of Clinical Oncology, 2004, 22, 2942-2953.	0.8	546
320	The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biology of Blood and Marrow Transplantation, 2004, 10, 794-804.	2.0	23
321	Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkinâ€™s Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.. Blood, 2004, 104, 1654-1654.	0.6	1
322	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.. Blood, 2004, 104, 2301-2301.	0.6	4
323	Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. Blood, 2004, 104, 5239-5239.	0.6	1
324	Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biology of Blood and Marrow Transplantation, 2003, 9, 330-340.	2.0	7

#	Article	IF	Citations
325	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 2003, 102, 3829-3836.	0.6	143
326	Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. British Journal of Haematology, 2002, 119, 131-134.	1.2	64
327	Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Research, 2002, 62, 6712-6.	0.4	45
328	Cationic Liposome-MediatedE1AGene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial. Journal of Clinical Oncology, 2001, 19, 3422-3433.	0.8	207
329	Melphalan and purine analogâ€“containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 2001, 97, 631-637.	0.6	551
330	E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy. Breast Cancer, 2001, 8, 285-293.	1.3	20
331	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. Transplant Infectious Disease, 2001, 3, 29-33.	0.7	5
332	Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer, 2001, 92, 1775-1782.	2.0	76
333	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. American Journal of Hematology, 2001, 67, 227-233.	2.0	23
334	Harnessing graftâ€versusâ€malignancy: nonâ€myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology, 2000, 111, 18-29.	1.2	6
335	High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends. Clinical Breast Cancer, 2000, 1, 197-209.	1.1	7
336	ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY. Hematology/Oncology Clinics of North America, 1999, 13, 1041-1057.	0.9	44
337	Primary malignant teratoma of the thyroid gland: Report and discussion of two cases. , 1998, 20, 649-653.		14
338	Primary malignant teratoma of the thyroid gland: Report and discussion of two cases. , 1998, 20, 649.		2
339	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 1997, 15, 953-960.	2.6	86
340	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemotherapy and Pharmacology, 1997, 40, 321-329.	1.1	242
341	Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Annals of Surgical Oncology, 0, , .	0.7	2